미분류

Samsung Bioepis’ diabetes treatment under FDA review for sale

By 최희석
  • Published : Aug 8, 2016 - 17:06
  • Updated : Aug 8, 2016 - 17:10
[THE INVESTOR] The US Food and Drug Administration has begun reviewing the diabetes treatment SB9 for sale in the US, local media reported on Aug. 8.

SB9, developed by MSD in collaboration with Samsung Bioepis, is a biosimilar of Lantus developed by Sanofi. 

Samsung Bioepis is an affiliate of Korean tech giant Samsung Electrioncs.



According to reports, SB9 could be approved for sale by the end of next year.

Including SB9, Samsung Bioepis has six biosimilar products in the works. Of the six, two treatments for autoimmune conditions have been approved in South Korea and Europe.

By Choi He-suk (cheesuk@heraldcorp.com)